Study Name:
A PHASE 2 STUDY OF ALISERTIB IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER
Targeted Disease(s):
Lung Cancer
Purpose of Study:
ALISCA-Lung1 is a clinical trial that is exploring whether an investigational medication called alisertib is effective in treating patients with pathologically confirmed small cell lung cancer following progression on or after treatment with one platinum-based chemotherapy and an anti-PD-L1 immunotherapy agent. Up to one additional systemic anti-cancer therapy for SCLC is allowed, for a total of up to two prior lines of therapy. Eligible patients must be at least 18 years old and cannot have used an AURKA specific-targeted or pan-Aurora-targeted agent, including alisertib in any setting. There are additional inclusion and exclusion criteria. The investigator at the study center will determine if you meet all of the criteria.
Study Dates:
February 8, 2024 - January 31, 2026
Type of Study:
Pre-Market
Study Design:
Controlled Design
Study Location:
Nationwide
Sponsors:
Puma Biotechnology, Inc.
Contact:
424-248-6500
ClinicalTrails.gov Identifier:
NCT06095505
